VRN101099

DRUG2 trials

Sponsors

Voronoi, Inc

Conditions

HER2-positive Solid TumorsHealthy Adult

Phase 1

A Study of VRN101099 in Patients With HER2-Positive Solid Tumors

RecruitingNCT06806982

Voronoi, IncHER2-positive Solid Tumors

Start: 2025-02-17End: 2027-07-31Target: 72Updated: 2025-08-28

Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants

RecruitingNCT07550946

Voronoi, IncHealthy Adult

Start: 2026-06-22End: 2026-09-30Target: 24Updated: 2026-08-21

Related Papers

Phase Ia study of VRN101099, a brain-penetrant, highly selective covalent HER2 inhibitor, in HER2-positive or HER2-mutant advanced solid tumors.

Journal of Clinical Oncology2026-05-27